Robert N. Young
Burnaby, BC V5A1S6, Canada
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 36 publications
Author Correction: E-type prostanoid receptor 4 drives resolution of intestinal inflammation by blocking epithelial necroptosis.
Journal: Nature cell biology
Published: December 22, 2025
Pharmacokinetics, pathology and efficacy of SARS-CoV-2 main protease inhibitor VPC285785 in a murine model of coronavirus infection.
Journal: Scientific reports
Published: May 08, 2025
Functional and Structural Characterization of Treatment-Emergent Nirmatrelvir Resistance Mutations at Low Frequencies in the Main Protease (Mpro) Reveals a Unique Evolutionary Route for SARS-CoV-2 to Gain Resistance.
Journal: The Journal of infectious diseases
Published: November 15, 2024
Development of novel GI-centric prostaglandin E2 receptor type 4 (EP4) agonist prodrugs as treatment for ulcerative colitis and other intestinal inflammatory diseases.
Journal: Bioorganic & medicinal chemistry letters
Published: May 11, 2024
A novel class of broad-spectrum active-site-directed 3C-like protease inhibitors with nanomolar antiviral activity against highly immune-evasive SARS-CoV-2 Omicron subvariants.
Journal: Emerging microbes & infections
Published: August 09, 2023
Large-Scale Virtual Screening for the Discovery of SARS-CoV-2 Papain-like Protease (PLpro) Non-covalent Inhibitors.
Journal: Journal of chemical information and modeling
Published: March 17, 2023
A protocol for identifying the binding sites of small molecules on the cystic fibrosis transmembrane conductance regulator (CFTR) protein.
Journal: STAR protocols
Published: April 18, 2022
Development of 2-(5,6,7-Trifluoro-1H-Indol-3-yl)-quinoline-5-carboxamide as a Potent, Selective, and Orally Available Inhibitor of Human Androgen Receptor Targeting Its Binding Function-3 for the Treatment of Castration-Resistant Prostate Cancer.
Journal: Journal of medicinal chemistry
Published: October 18, 2021
Lipid nanoparticle-mediated silencing of osteogenic suppressor GNAS leads to osteogenic differentiation of mesenchymal stem cells in vivo.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: October 15, 2021
Design, Synthesis, Pharmacokinetics, and Biodistribution of a Series of Bone-Targeting EP4 Receptor Agonist Prodrugs for Treatment of Osteoporosis and Other Bone Conditions.
Journal: ACS pharmacology & translational science
Published: January 18, 2021
Effects of treatment with a bone-targeted prostaglandin E2 receptor 4 agonist C3 (Mes-1007) in a mouse model of severe osteogenesis imperfecta.
Journal: Bone
Published: December 27, 2020
E-type prostanoid receptor 4 drives resolution of intestinal inflammation by blocking epithelial necroptosis.
Journal: Nature cell biology
Published: November 27, 2020
Last Updated: 09/26/2026